The effect of Hydrocortisone,Vitamin C and Thiamine in treatment of patients with severe Sepsis/Septic shock

The effect of Hydrocortisone,Vitamin C and Thiamine in treatment of patients with severe Sepsis/Septic shock in ICU

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220219054058N1

Enrollment

Registered

2022-03-01

Start date

2022-03-01

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic shock,severe sepsis. Severe sepsis with septic shock

Interventions

Intervention 1: Intervention group: Patients in this group receive combined three drugs of Hydrocortisone (50 mg every 6 hours intravenously - Jaber Bin Hayan Pharmaceutical Company, Iran), Thiamine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: NO covid 19 Disease(PCR negative) Age 18or higher No pregnancy No G6PD deficiency No initial diagnosis of: Stroke, Acute Coronary syndrome, Active Gastrointestinal bleeding, Burns and Trauma No use of vasopressors more than 24 hours before entering the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mortality rate, Duration of intubation, Duration of stay in the intensive care unit, Duration of vasopressor, CRP, Lactate, Severity of illness. Timepoint: Mortality at the end of 7 days, Intubation period up to 7 days, Mean daily disease intensity up to 3 days, Mean CRP level on the first, third and fifth day, Duration of stay in intensive care unit up to 7 days, Duration of hospital stay, Mean level Lactate on the first, third and fifth day, Duration of receiving vasopressor up to 7 days. Method of measurement: Questionnaire filled out by Intern.	—

Measure

Time frame

Mortality rate, Duration of intubation, Duration of stay in the intensive care unit, Duration of vasopressor, CRP, Lactate, Severity of illness. Timepoint: Mortality at the end of 7 days, Intubation period up to 7 days, Mean daily disease intensity up to 3 days, Mean CRP level on the first, third and fifth day, Duration of stay in intensive care unit up to 7 days, Duration of hospital stay, Mean level Lactate on the first, third and fifth day, Duration of receiving vasopressor up to 7 days. Method of measurement: Questionnaire filled out by Intern.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMobina Hosseini

Arak University of Medical Sciences

Mobinaaahosseini@gmail.com+98 86 3222 4617

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026